Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6–18 Years with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Detalles Bibliográficos
Autores principales: Bennett, Nancy M., Pilishvili, Tamara, Whitney, Cynthia G., Moore, Matthew, Gierke, Ryan, Harris, Aaron M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: U.S. Centers for Disease Control 2013
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604951/
https://www.ncbi.nlm.nih.gov/pubmed/23803961
_version_ 1782395144192917504
author Bennett, Nancy M.
Pilishvili, Tamara
Whitney, Cynthia G.
Moore, Matthew
Gierke, Ryan
Harris, Aaron M.
author_facet Bennett, Nancy M.
Pilishvili, Tamara
Whitney, Cynthia G.
Moore, Matthew
Gierke, Ryan
Harris, Aaron M.
author_sort Bennett, Nancy M.
collection PubMed
description
format Online
Article
Text
id pubmed-4604951
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher U.S. Centers for Disease Control
record_format MEDLINE/PubMed
spelling pubmed-46049512018-01-17 Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6–18 Years with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Bennett, Nancy M. Pilishvili, Tamara Whitney, Cynthia G. Moore, Matthew Gierke, Ryan Harris, Aaron M. MMWR Morb Mortal Wkly Rep Articles U.S. Centers for Disease Control 2013-06-28 /pmc/articles/PMC4604951/ /pubmed/23803961 Text en https://creativecommons.org/publicdomain/zero/1.0/All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.
spellingShingle Articles
Bennett, Nancy M.
Pilishvili, Tamara
Whitney, Cynthia G.
Moore, Matthew
Gierke, Ryan
Harris, Aaron M.
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6–18 Years with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
title Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6–18 Years with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
title_full Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6–18 Years with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
title_fullStr Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6–18 Years with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
title_full_unstemmed Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6–18 Years with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
title_short Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6–18 Years with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
title_sort use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6–18 years with immunocompromising conditions: recommendations of the advisory committee on immunization practices (acip)
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604951/
https://www.ncbi.nlm.nih.gov/pubmed/23803961
work_keys_str_mv AT bennettnancym useof13valentpneumococcalconjugatevaccineand23valentpneumococcalpolysaccharidevaccineamongchildrenaged618yearswithimmunocompromisingconditionsrecommendationsoftheadvisorycommitteeonimmunizationpracticesacip
AT pilishvilitamara useof13valentpneumococcalconjugatevaccineand23valentpneumococcalpolysaccharidevaccineamongchildrenaged618yearswithimmunocompromisingconditionsrecommendationsoftheadvisorycommitteeonimmunizationpracticesacip
AT whitneycynthiag useof13valentpneumococcalconjugatevaccineand23valentpneumococcalpolysaccharidevaccineamongchildrenaged618yearswithimmunocompromisingconditionsrecommendationsoftheadvisorycommitteeonimmunizationpracticesacip
AT moorematthew useof13valentpneumococcalconjugatevaccineand23valentpneumococcalpolysaccharidevaccineamongchildrenaged618yearswithimmunocompromisingconditionsrecommendationsoftheadvisorycommitteeonimmunizationpracticesacip
AT gierkeryan useof13valentpneumococcalconjugatevaccineand23valentpneumococcalpolysaccharidevaccineamongchildrenaged618yearswithimmunocompromisingconditionsrecommendationsoftheadvisorycommitteeonimmunizationpracticesacip
AT harrisaaronm useof13valentpneumococcalconjugatevaccineand23valentpneumococcalpolysaccharidevaccineamongchildrenaged618yearswithimmunocompromisingconditionsrecommendationsoftheadvisorycommitteeonimmunizationpracticesacip

Ejemplares similares